A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline

Soares, Adriana de Almeida; Louçana, Polyanna Mendes Camarço; Nasi, Ema Pereira; Sousa, Kamila Maria de Holanda; Sá, Odara Maria de Sousa; Silva‐Néto, Raimundo Pereira

doi:10.1080/1028415x.2016.1266133

Cited by 26 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The subcutaneous‐administered CGRP MAb onset of action was observed within the first week while IV MAb formulation may work even after the first day . The clinical therapeutic effect seems to persist over 6 months and even up to a year (open‐label extension data) with a MMD change of 4.2‐5.3 absolute days . A portion of the initial poor responders in the double‐blind studies of fremanezumab and galcanezumab later became responders in the open‐label study .…”

Section: Cgrp Function‐blocking Therapy In Migraine and Cluster Headachementioning

confidence: 98%

“…26,33 The clinical therapeutic effect seems to persist over 6 months and even up to a year (open-label extension data) with a MMD change of 4.2-5.3 absolute days. 31,[34][35][36] A portion of the initial poor responders in the doubleblind studies of fremanezumab and galcanezumab later became responders in the open-label study. 37,38 In short, CGRP MAbs work in preventing EM, even in some of the initial non-responders.…”

Section: Cgrp Function-blocking Therapy In Migraine and Cluster Headachementioning

confidence: 99%

See 1 more Smart Citation

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review

2019

View full text Add to dashboard Cite

Calcitonin‐gene‐related peptide (CGRP), a neuropeptide broadly distributed in neuronal and non‐neuronal regions throughout the body, plays a fundamental role in migraine and cluster headache (CH) pathophysiology. CGRP functional blockade alleviates neurogenic inflammation and reduces pain pathway sensitization. Two types of CGRP function‐blocking modalities, monoclonal antibodies (MAbs), and small molecules (gepants), have been designed to target the CGRP ligands and CGRP receptors. In this narrative review, we summarized the latest clinical trials on gepants and CGRP function‐blocking MAbs for migraine and CH prevention. At the time of writing, newer gepants are currently under Federal Drug Administration (FDA) review for migraine management, but there is no study yet on the usage of gepants for CH. Erenumab, fremanezumab, and galcanezumab have been approved by the FDA for migraine prevention while eptinezumab is under FDA review. CGRP MAbs are as effective as and more tolerable than conventional migraine preventives. For CH prevention, galcanezumab has shown some promising findings and was recently approved for use in episodic cluster prevention. CGRP function‐blocking therapy not only demonstrates high efficacy and superior safety profile, but also improves headache frequency and quality of life. Convenient monthly dosing for the MAbs can further improve medication adherence, hence better headache control. With CGRP function‐blocking therapy showing efficacy even in individuals who failed other preventives, it has become an exciting new therapeutic option in the field of migraine and CH.

show abstract

Section: Cgrp Function‐blocking Therapy In Migraine and Cluster Headachementioning

confidence: 98%

Section: Cgrp Function-blocking Therapy In Migraine and Cluster Headachementioning

confidence: 99%

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review

2019

View full text Add to dashboard Cite

show abstract

“…Soares et al tested in a double-blind, randomized placebo-controlled clinical trial the benefits of omega-3 polyunsaturated fatty acids for the prevention of migraine in headache patients using amitriptyline. After 60 days, the authors noticed a reduction of days of headache in their patients and underlined the good capacity of omega-3 in prevention of migraine attacks [49].…”

Section: Enriched Polyunsaturated Fatty Acid Dietsmentioning

confidence: 88%

Dietary Patterns and Interventions to Alleviate Chronic Pain

et al. 2020

View full text Add to dashboard Cite

Pain is one of the main problems for modern society and medicine, being the most common symptom described by almost all patients. When pain becomes chronic, the life of the patients is dramatically affected, being associated with significant emotional distress and/or functional disability. A complex biopsychosocial evaluation is necessary to better understand chronic pain, where good results can be obtained through interconnected biological, psychological, and social factors. The aim of this study was to find the most relevant articles existent in the PubMed database, one of the most comprehensive databases for medical literature, comprising dietary patterns to alleviate chronic pain. Through a combined search using the keywords “chronic pain” and “diet” limited to the last 10 years we obtained 272 results containing the types of diets used for chronic pain published in the PubMed database. Besides classical and alternative methods of treatment described in literature, it was observed that different diets are also a valid solution, due to many components with antioxidant and anti-inflammatory qualities capable to influence chronic pain and to improve the quality of life. Thirty-eight clinical studies and randomized controlled trials are analyzed, in an attempt to characterize present-day dietary patterns and interventions to alleviate chronic pain.

show abstract

“…The authors affirm that this beneficial effect of omega-3 FAs could be due to the decrease in the production of prostaglandins and leukotrienes or to a change in the synthesis and release of serotonin by platelets. [ 66 ]…”

Section: Discussionmentioning

confidence: 99%

Clinical use of omega-3 fatty acids in migraine

et al. 2020

View full text Add to dashboard Cite

Background: Omega-3 fatty acids (FAs) can produce several beneficial effects and are commonly used for the treatment of migraine symptoms. Although current therapeutic measures for migraine included pharmacological therapies, dietary supplements, and herbal ingredients, dietary patterns, acupuncture, relaxation techniques, biofeedback, and psychotherapy, omega-3 FAs therapeutic role seems to be obtained through the inhibition or reduction of the release of inflammatory cytokines. The present review aims to provide updated information about the effects of omega-3 FAs in migraine treatment, investigating their clinical effects alone or in combination with other substances. Methods: Bibliographic research was conducted by examining scientific literature from January 2000 until January 31, 2020. Ten clinical studies were included in the review. Quality assessment of randomized controlled trials was performed by using the JADAD scale. Results: Clinical studies methodology is not always of good quality and results show moderate evidence concerning the therapeutic role of omega-3 FAs in migraine. Conclusion: Further clinical trials are necessary to implement the knowledge concerning the use of omega-3 fatty acids in the treatment of migraine.

show abstract

A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline

Abstract: Polyunsaturated omega 3 fatty acids (OPFAϖ-3) are useful for prophylaxis of migraine attacks.

Cited by 26 publications

References 20 publications

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review

Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review

Dietary Patterns and Interventions to Alleviate Chronic Pain

Clinical use of omega-3 fatty acids in migraine

Contact Info

Product

Resources

About